Chronic Heart Failure | Treatment Algorithms: Claims Data Analysis | US | 2025
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market is heavily genericized, and prescribers have many drug and drug class options, creating a high barrier to the uptake of novel branded agents. RAAS inhibitors and beta blockers are the first-line treatment for CHF, usually in combination with diuretics when fluid overload is present. The addition of a second- or third-line treatment is often needed to better manage the disease. The SGLT-2 inhibitors have become the next blockbuster drugs in the CHF market, and the use of Entresto (sacubitril / valsartan) is also expanding. This report provides important insight into how these agents are used in the management of CHF and how practices are evolving.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CHF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CHF patients?
- How have SGLT-2 inhibitors been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of CHF patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of CHF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Markets covered: United States
Key companies: Pfizer, Merck & Co., Novartis, GSK, AstraZeneca, Johnson & Johnson innovative medicine, Eli Lilly, Boehringer Ingelheim, Amgen
Key drugs: ACE inhibitors, ARBs, beta blockers, MRAs, diuretics, CCBs, nitrates, ivabradine, vericiguat, Entresto (sacubitril / valsartan), SGLT-2 inhibitors
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
